Latest Intelligence

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

3M Health Care and Greystone sign licensing agreement

3M Health Care and Greystone Pharmaceuticals have entered into an exclusive, worldwide license agreement for wound care products using Greystone's patented polyhydrated ionogens technology, a proprietary formulation that aids in the management of hard-to-heal wounds.

Published By MarketLine
18 Jul 2008
NewsWire
NewsWire

3M launches ICD-10 financial impact analysis tool and services

3M Health Information Systems, the health care IT division of 3M Company, has launched a new ICD-10 financial impact analysis tool and ICD-10 financial impact consulting services.

Published By MarketLine
10 Jul 2012
NewsWire
NewsWire

3M launches ICD-10 financial impact analysis tool and services

3M Health Information Systems has launched a new ICD-10 financial impact analysis tool and ICD-10 financial impact consulting services.

Published By MarketLine
05 Jul 2012
NewsWire
NewsWire

3M launches software to promote medical necessity compliance

3M Health Information Systems, has integrated its Medical Necessity Online and Ambulatory Revenue Management Software, to provide access to all pre-service medical necessity data.

Published By MarketLine
05 Nov 2007
NewsWire
NewsWire

3M launches two new respirators

3M has introduced two new Niosh N95 respirators for use by the general public in public health medical emergencies.

Published By MarketLine
19 May 2008
NewsWire
NewsWire

3M licenses Cambridge Consultants's dry powder inhaler technology

3M, a diversified technology company, has announced that its drug delivery systems division has signed an exclusive technology licensing and purchase agreement with Cambridge Consultants for its Conix dry powder inhaler technology platform.

Published By MarketLine
11 Dec 2008
NewsWire
NewsWire

3M Pharmaceuticals granted FDA approval for Aldara

3M has confirmed that the FDA has approved its Aldara product, the first prescription therapy in nearly a decade for the treatment of superficial basal cell carcinoma, a type of nonmelanoma skin cancer.

Published By MarketLine
16 Jul 2004
NewsWire
NewsWire

3M Reports First Quarter Results And Announces Company Restructuring

Published By MarketLine
23 Apr 2001
NewsWire
NewsWire

3M reports Phase II genital herpes trial results and Phase III initiation

Published By MarketLine
03 Nov 2000
NewsWire
NewsWire

3M Reports Third-Quarter, Nine-Month Results

3M has reported sales and earnings for the third quarter and first nine months of 2001. Third-quarter net income - excluding non-recurring items - totaled $437 million, or $1.10 per share, down 12 percent from $499 million, or $1.25 per share, in the same quarter of 2000. Currency effects reduced earnings for the quarter by 6 cents per share, or 5 percent.

Published By MarketLine
22 Oct 2001

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.